focus -WSS

focus

author：comprehensive 2025-09-30 02:09:27 - browse：3117

Photo illustration of Chris Viehbacher -- biotech coverage from STAT — Chris Viehbacher took over as Biogen CEO in November. Suzanne Kreiter/Globe staff; Photo illustration Alex Hogan/STAT

This was supposed to be the new Biogen. When Chris Viehbacher, a respected pharmaceutical executive, took over as CEO in November, Wall Street saw him as a steadying force for the wayward company and a strong personality who would stand up to its quarrelsome board.

Instead, Biogen’s board has saddled Viehbacher with the first crisis of his tenure at the company. Alex Denner, a long-time director, nominated a biotech executive who is also the mother of his child to succeed him on the board, and Biogen chose not to disclose the couple’s relationship to shareholders, an omission that shocked people close to the company and undermined the notion that Biogen was changing for the better.

“It’s just disappointing to see after all the criticism that has been levied at the company over the last few years, there really seems to be no self-awareness going into this recommendation,” said Brian Skorney, a securities analyst at Baird who covers Biogen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： People can get long Covid without testing positive for virus: Study

hotspot

WSS

People can get long Covid without testing positive for virus: Study

Think you might have Covid

The surgeon had a dilemma only a Nazi medical text could resolve

NIH director takes cautious approach to Biden drug pricing priority

Health officials lay out plans to cope with respiratory virus season

How digital therapeutics firms are pivoting after Pear's bankruptcy

focus

focus

leisure time

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Abortion policy in the spotlight at Republican debate

Activists slam private health insurers over coverage restrictions

People can get long Covid without testing positive for virus: Study

The cancer drug shortage isn’t new — and neither are the solutions

NIH director takes cautious approach to Biden drug pricing priority

FDA approval of Sarepta Duchenne genetic therapy gives me hope

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

Medical records are filled with copy

Study: Spinal cord stimulation helps patients with paralysis walk again

hotspot

Wegovy improves function in certain heart failure patients

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Wegovy improves function in certain heart failure patients

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

California store owner shot dead in dispute over displaying Pride flag: Police

Prior authorization will have to move faster under new Biden rule

hotspot

entertainment

hotspot

entertainment